Direct evidence that spinal serotonin and noradrenaline terminals mediate the spinal antinociceptive effects of morphine in the periaqueductal gray.
D000818:Animals; D002535:Cerebral Aqueduct / Q000187:drug effects*; D007278:Injections, Spinal; D008784:Methysergide / Q000494:pharmacology; D009020:Morphine / Q000494:pharmacology*; D009433:Neural Inhibition / Q000187:drug effects; D009619:Nociceptors / Q000187:drug effects* / Q000502:physiology; D009638:Norepinephrine / Q000502:physiology*; D010646:Phentolamine / Q000494:pharmacology; D051381:Rats; D011941:Receptors, Adrenergic / Q000187:drug effects / Q000502:physiology*; D011985:Receptors, Serotonin / Q000187:drug effects / Q000502:physiology*; D012701:Serotonin / Q000502:physiology*; D013116:Spinal Cord / Q000187:drug effects / Q000502:physiology*
D011941:Receptors, Adrenergic; D011985:Receptors, Serotonin; D012701:Serotonin; D009020:Morphine; D009638:Norepinephrine; D008784:Methysergide; D010646:Phentolamine